Beacon Discovery Celebrates First Anniversary And Announces Collaborations With Two San Diego Start-Ups
September 14, 2017
BEACON DISCOVERY CELEBRATES FIRST ANNIVERSARY AND ANNOUNCES COLLABORATIONS WITH TWO SAN DIEGO START-UPS
Since its launch in September last year, Beacon has been consolidating its drug discovery operations and advancing a number of internal drug discovery programs. Beacon is developing alliances with local, national and international partners. As a first step in this process we are delighted to announce the initiation of research collaborations on GPCR targets with two San Diego startups. One of these start-ups is Pipeline Therapeutics.
Pipeline Therapeutics is a San Diego-based biotechnology company backed by Versant Ventures, with a focus on neurodegenerative diseases. As they assemble a world-class research team, Pipeline will work with Beacon on assay development and high-throughput screening (HTS) for an orphan GPCR target. In addition, Beacon will assist with a more advanced project where our expertise in a wide range of receptor binding and functional assays should accelerate the launch of Pipeline’s discovery programs in this important disease area.
Visit: www.pipelinetherapeutics.com.
BEACON DISCOVERY CELEBRATES FIRST ANNIVERSARY AND ANNOUNCES COLLABORATIONS WITH TWO SAN DIEGO START-UPS
Since its launch in September last year, Beacon has been consolidating its drug discovery operations and advancing a number of internal drug discovery programs. Beacon is developing alliances with local, national and international partners. As a first step in this process we are delighted to announce the initiation of research collaborations on GPCR targets with two San Diego startups. One of these start-ups is Pipeline Therapeutics.
Pipeline Therapeutics is a San Diego-based biotechnology company backed by Versant Ventures, with a focus on neurodegenerative diseases. As they assemble a world-class research team, Pipeline will work with Beacon on assay development and high-throughput screening (HTS) for an orphan GPCR target. In addition, Beacon will assist with a more advanced project where our expertise in a wide range of receptor binding and functional assays should accelerate the launch of Pipeline’s discovery programs in this important disease area.
Visit: www.pipelinetherapeutics.com.
Questions? Contact Us
You can easily get in touch with a Eurofins Discovery Expert or get help from our Customer Service team. Reach out with questions, or to discuss your specific discovery challenges.
